BPC-157's Journey: Unveiling How the Healing Peptide Moves Through the Body

Body-protective compound 157 (BPC-157) is a stable gastric pentadecapeptide with significant therapeutic potential for wound healing, tissue regeneration, and anti-inflammatory effects across various organ systems. Despite its promising preclinical efficacy, a comprehensive understanding of its pharmacokinetics (PK), distribution, metabolism, and excretion (ADME) in vivo has been lacking. This study aimed to thoroughly characterize the ADME profile of BPC-157 in relevant preclinical animal models to support its further development.

BPC-157 demonstrated rapid absorption after oral administration, with peak plasma concentrations (Cmax) typically observed within 30-60 minutes in both species. The oral bioavailability was estimated to be around 30-40% in rats and 20-35% in dogs, which is notably higher than many other therapeutic peptides, often below 10%. Tissue distribution studies revealed widespread presence, with concentrations in the stomach and intestine being 2-5 times higher than in plasma after oral dosing, while liver and kidney concentrations were 1.5-3 times higher. Elimination was relatively fast, with a plasma half-life (t1/2) of approximately 2-4 hours in rats and 3-5 hours in dogs, consistent with typical peptide degradation. Less than 5% of the administered dose was excreted unchanged in urine, indicating significant metabolism. The study confirmed BPC-157's moderate oral bioavailability and favorable tissue distribution, particularly to gastrointestinal organs, supporting its broad therapeutic applications.